BAY CITY CAPITAL LLC
CIK 1288452 · last filed 2021-10-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$84.50M
Companies
12
Total Filings
23
Lifetime Open-Market Net
-$489.64M
Filer Profile
Reported Address
750 BATTERY STREET STE 400SAN FRANCISCO, CA 94111
Phone
(415) 676-3830
State of Incorporation
DE
Formerly Known As
BAY CITY CAPITAL FUND LLC (2005–2005)
Related Filers
Bay City Capital Fund V Co-Investment Fund, L.P. — 34 joint filings, latest 2020-03-16
Bay City Capital Fund V, L.P. — 34 joint filings, latest 2020-03-16
Bay City Capital Management V LLC — 34 joint filings, latest 2020-03-16
BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP — 33 joint filings, latest 2021-12-07
Bay City Capital Fund IV, L.P. — 33 joint filings, latest 2021-12-07
CARL GOLDFISCHER — 1 joint filings, latest 2020-03-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XLO | 10%+ Owner | 58,356 | $9.00 | $525.2K | $5.00M | 1 | 2021-10-26 |
| MDGL | Director | 154,255 | $541.08 | $83.46M | -$586.74M | 3 | 2020-05-29 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | 10%+ Owner | 175,845 | $14.59 | $2.57M | $0 | 1 | 2020-03-16 |
| Kezar Life Sciences, Inc. (KZR) Delisted | 10%+ Owner | 62,223 | $7.29 | $453.6K | $2.25M | 1 | 2018-06-28 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 3,013,966 | $18.62 | $56.12M | -$2.34M | 4 | 2015-07-28 |
| NEVRO CORP (NVRO) Delisted | 42,658 | $5.84 | $249.1K | $0 | 1 | 2014-11-12 | |
| DERM | Director | 65,572 | $7.86 | $515.4K | $4.42M | 1 | 2014-10-08 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | 10%+ Owner | 2,221,067 | — | — | $0 | 3 | 2013-07-19 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 3,492,063 | $1.47 | $5.13M | $10.00M | 1 | 2013-06-07 |
| ReShape Weightloss Inc. (ETRM) Delisted | 10%+ Owner | 51,451 | — | — | $11.83M | 3 | 2010-12-16 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | 10%+ Owner | 219,284 | — | — | $39.52M | 2 | 2007-08-08 |
| PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | 10%+ Owner | 4,383,684 | — | — | $26.42M | 1 | 2007-04-30 |
Recent Filings · Page 3 of 3
23 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-08-08 | VIA Pharmaceuticals, Inc. (VIAP) Delisted | Buy (P) | +16,263,928 | $39.52M | EDGAR |
| 2007-06-07 | VIA Pharmaceuticals, Inc. (VIAP) Delisted | Other (J) | +33,573,708 | $0 | EDGAR |
| 2007-04-30 | PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | Buy (P) | +4,174,064 | $26.42M | EDGAR |
Showing 21–23 of 23
Prev
Page 3 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.